Effect of DAA therapy in hepatitis C treatment — an impulsive control approach

Effect of DAA therapy in hepatitis C treatment — an impulsive control approach

In this article, we have presented a mathematical model to study the dynamics of hepatitis C virus (HCV) disease considering three populations namely the uninfected liver cells, infected liver cells, and HCV with the aim to control the disease. The model possesses two equilibria namely the disease-f...

Full description

Bibliographic Details
Main Authors:	Amar Nath Chatterjee, Fahad Al Basir, Yasuhiro Takeuchi
Format:	Article
Language:	English
Published:	AIMS Press 2021-04-01
Series:	Mathematical Biosciences and Engineering
Subjects:	hepatitis c daa therapy mathematical model basic reproduction number impulsive control drug adherence
Online Access:	http://www.aimspress.com/article/doi/10.3934/mbe.2021075?viewType=HTML

Similar Items

Antioxidants benefits in hepatitis C infection in the new DAAs era
by: Sonia A. Lozano-Sepúlveda, et al.
Published: (2019-05-01)

EVALUATION OF LIVER FIBROSIS AND CAROTID INTIMA-MEDIA THICKNESS INDEX (C-IMT) IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS BEFORE AND AFTER DIRECT-ACTING ANTIVIRAL TREATMENT (DAA)
by: Raluca Mihaela Dîrțu, et al.
Published: (2021-06-01)

Threshold dynamics of a delayed predator–prey model with impulse via the basic reproduction number
by: Xiangsen Liu, et al.
Published: (2018-12-01)

Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review
by: Lorenzo Onorato, et al.
Published: (2021-03-01)

HCC in the Era of Direct-Acting Antiviral Agents (DAAs): Surgical and Other Curative or Palliative Strategies in the Elderly
by: Stefania Brozzetti, et al.
Published: (2021-06-01)

Study of hepatitis B virus infection, reactivation among patients with chronic hepatitis C infection treated by direct antiviral agents (DAAs)
by: Haitham A. Azeem, et al.
Published: (2021-06-01)

HEPATITIS C VIRUS – FROM UNKNOWN VIRUS TO A CURABLE DISEASE
by: Raluca Mihaela Dirtu, et al.
Published: (2019-06-01)

Peripheral PD-1+ T Cells Co-expressing Inhibitory Receptors Predict SVR With Ultra Short Duration DAA Therapy in HCV Infection
by: Sara Romani, et al.
Published: (2019-06-01)

Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection
by: Julia L. Casey, et al.
Published: (2019-04-01)

Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus
by: Tavares RCF, et al.
Published: (2018-10-01)

New treatment of hepatitis C (Direct Acting Antiviral)
by: Mohsen Akhondi-Meybodi
Published: (2019-10-01)

Management Of Patients With Hepatitis B Virus Reactivation Post–DAA Treatment Of Chronic Hepatitis C Virus Infection In HCV–HBV Coinfected Patients With Pretreatment HBeAg Seroconversion And Early Degree Of Hepatic Fibrosis
by: Osman HA, et al.
Published: (2019-09-01)

Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO‐C): An open‐label, single‐arm, phase 4, multicentre trial
by: Jason Grebely, et al.
Published: (2020-06-01)

The hepatitis C treatment revolution: how to avoid Asia missing out
by: Nick Walsh, et al.
Published: (2015-10-01)

State and prospects of therapeutic treatment of children with chronic hepatitis C in the Russian Federation
by: A. A. Fomicheva, et al.
Published: (2021-03-01)

Dynamics of a delayed plant disease model with Beddington-DeAngelis disease transmission
by: Fahad Al Basir, et al.
Published: (2021-04-01)

Modelling and analysis of a within-host model of hepatitis B and D co-infections
by: Plaire Tchinda Mouofo, et al.
Published: (2018-08-01)

Virological and Clinical Outcome of DAA Containing Regimens in a Cohort of Patients in Calabria Region (Southern Italy)
by: Vincenzo Scaglione, et al.
Published: (2020-02-01)

Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC
by: Gao X, et al.
Published: (2020-12-01)

Treatment of hepatitis C virus infection and associated glomerular disease
by: Delia-Georgiana Tudorovici, et al.
Published: (2020-09-01)

Detection of low-level HCV variants in DAA treated patients: comparison amongst three different NGS data analysis protocols
by: Valeria Caputo, et al.
Published: (2020-07-01)

Resistance Mutations A30K and Y93N Associated with Treatment Failure with Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection Non-Responder Patients: Case Reports
by: Vanessa D. Costa, et al.
Published: (2019-10-01)

A proof-of-concept study in HCV-infected Huh7.5 cells for shortening the duration of DAA-based triple treatment regimens
by: Hu Li, et al.
Published: (2019-08-01)

Modélisation sémantique du cloud computing : vers une composition de services DaaS à sémantique incertaine
by: Malki, Abdelhamid
Published: (2015)

Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens
by: Ghias Un Nabi Tayyab, et al.
Published: (2020-04-01)

Outcomes of a tertiary-based innovative approach to engage primary care providers in provision of hepatitis C treatment in community settings
by: Davoud Pourmarzi, et al.
Published: (2019-10-01)

Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study
by: Filomena Morisco, et al.
Published: (2021-07-01)

2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populationsRecommendationsRecommendationsRecommendationsRecommendationsRecommendationsRecommendationsRecommendationsRecommendationsRecommendationsRecommendationsRecommendationsRecommendationsRecommendationsRecommendations
by: Ming-Lung Yu, et al.
Published: (2020-07-01)

Molecular characterization of hepatitis C virus in liver disease patients in Botswana: a retrospective cross-sectional study
by: Lynnette Bhebhe, et al.
Published: (2019-10-01)

Real‐world effectiveness of direct‐acting antiviral agents for chronic hepatitis C patients with genotype‐2 infection after completed treatment
by: Tzu‐Sheng Cheng, et al.
Published: (2021-04-01)

Correlation between IL28B/TLR4 genetic variants and HCC development with/without DAAs treatment in chronic HCV patients
by: Ghada M. Salum, et al.
Published: (2020-09-01)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
by: Elfi Egmond, et al.

A dynamic model and some strategies on how to prevent and control hepatitis c in mainland China
by: Wanru Jia, et al.
Published: (2019-08-01)

Homelessness and Hepatitis C: risk factors and treatment
by: Goicoechea, Steven C.
Published: (2018)

Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: a real-world cohort
by: Bernuth S, et al.
Published: (2017-07-01)

Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis
by: Leonardo Frazzoni, et al.
Published: (2021-04-01)

Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy
by: Jacob A. Langness, et al.
Published: (2017-05-01)

Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents
by: Ghweil AA, et al.
Published: (2019-04-01)

Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia
by: Tengiz Tsertsvadze, et al.
Published: (2020-01-01)

Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China
by: Huan Xia, et al.
Published: (2020-05-01)